MDM2 and hepatocellular carcinoma: The explanation for preferentially increased HCC risk of MDM2 SNP309 polymorphism in HCV positive patients but not in HBV positive subgroup is that the TP53 function in the HCV patients could have been indirectly suppressed by the heightened MDM2 levels, making them more vulnerable to cancer development.